A Single-Pot Template Reaction Towards a Manganese-Based Contrast Agent

Overview

Journal Angew Chem Weinheim Bergstr Ger

Date 2024 Mar 20

PMID 38505690

Authors

Sellamuthu Anbu

Sabrina H L Hoffmann

Fabio Carniato

Lawrence Kenning

Thomas W Price

Timothy J Prior

Mauro Botta

Andre F Martins

Graeme J Stasiuk

Affiliations

Soon will be listed here.

Abstract

Manganese-based contrast agents (MnCAs) have emerged as suitable alternatives to gadolinium-based contrast agents (GdCAs). However, due to their kinetic lability and laborious synthetic procedures, only a few MnCAs have found clinical MRI application. In this work, we have employed a highly innovative single-pot template synthetic strategy to develop a MnCA, , and studied the most important physicochemical properties in vitro. displays optimized relaxivities at both medium (20 and 64 MHz) and high magnetic fields (300 and 400 MHz) and an enhanced =21.1 mM s (20 MHz, 298 K, pH 7.4) upon binding to BSA ( =4.2×10 M). In vivo studies show that is cleared intact into the bladder through renal excretion and has a prolonged blood half-life compared to the commercial GdCA Magnevist. shows great promise as a novel MRI contrast agent.

Citing Articles

A Single-Pot Template Reaction Towards a Manganese-Based Contrast Agent.

Anbu S, Hoffmann S, Carniato F, Kenning L, Price T, Prior T Angew Chem Weinheim Bergstr Ger. 2024; 133(19):10831-10839.

PMID: 38505690 PMC: 10947048. DOI: 10.1002/ange.202100885.

References

Laurent V, Corby S, Barbary C, Kermarrec E, Beot S, Regent D . [New possibilities to study biliary tree and gallbladder: functional magnetic resonance cholangiography contrast-enhanced with mangafodipir trisodium (Mn DPDP)]. J Radiol. 2007; 88(4):531-40. DOI: 10.1016/s0221-0363(07)89852-0. View

Troughton J, Greenfield M, Greenwood J, Dumas S, Wiethoff A, Wang J . Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem. 2004; 43(20):6313-23. DOI: 10.1021/ic049559g. View

Cloyd R, Koren S, Abisambra J . Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration. Front Aging Neurosci. 2019; 10:403. PMC: 6300587. DOI: 10.3389/fnagi.2018.00403. View

Tan M, Ye Z, Jeong E, Wu X, Parker D, Lu Z . Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents. Bioconjug Chem. 2011; 22(5):931-7. PMC: 3541050. DOI: 10.1021/bc100573t. View

Thomsen H, Morcos S, Dawson P . Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. Clin Radiol. 2006; 61(11):905-6. DOI: 10.1016/j.crad.2006.09.003. View

Forgacs A, Regueiro-Figueroa M, Barriada J, Esteban-Gomez D, de Blas A, Rodriguez-Blas T . Mono-, bi-, and trinuclear bis-hydrated Mn(2+) complexes as potential MRI contrast agents. Inorg Chem. 2015; 54(19):9576-87. DOI: 10.1021/acs.inorgchem.5b01677. View

Morrow J, Toth E . Next-Generation Magnetic Resonance Imaging Contrast Agents. Inorg Chem. 2017; 56(11):6029-6034. DOI: 10.1021/acs.inorgchem.7b01277. View

Dees A, Zahl A, Puchta R, van Eikema Hommes N, Heinemann F, Ivanovic-Burmazovic I . Water exchange on seven-coordinate Mn(II) complexes with macrocyclic pentadentate ligands: insight in the mechanism of Mn(II) SOD mimetics. Inorg Chem. 2007; 46(7):2459-70. DOI: 10.1021/ic061852o. View

Zhou Z, Lu Z . Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 5(1):1-18. PMC: 3552562. DOI: 10.1002/wnan.1198. View

10.

Forgacs A, Tei L, Baranyai Z, Esteban-Gomez D, Platas-Iglesias C, Botta M . Optimising the relaxivities of Mn complexes by targeting human serum albumin (HSA). Dalton Trans. 2017; 46(26):8494-8504. DOI: 10.1039/c7dt01508a. View

11.

Sieber M, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F . Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008; 18(10):2164-73. DOI: 10.1007/s00330-008-0977-y. View

12.

Lauffer R, Parmelee D, Dunham S, Ouellet H, Dolan R, Witte S . MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998; 207(2):529-38. DOI: 10.1148/radiology.207.2.9577506. View

13.

Shukla G, CHANDRA S, Seth P . Effect of manganese on the levels of DNA, RNA, DNase and RNase in cerebrum, cerebellum and rest of brain regions of rat. Acta Pharmacol Toxicol (Copenh). 1976; 39(5):562-9. DOI: 10.1111/j.1600-0773.1976.tb03206.x. View

14.

Eisinger J, FAWAZ-ESTRUP F, Shulman R . BINDING OF MN2+ TO NUCLEIC ACIDS. J Chem Phys. 1965; 42:43-53. DOI: 10.1063/1.1695717. View

15.

Aime S, Gianolio E, Terreno E, Giovenzana G, Pagliarin R, Sisti M . Ternary Gd(III)L-HSA adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. J Biol Inorg Chem. 2000; 5(4):488-97. DOI: 10.1007/pl00021449. View

16.

Xue S, Yang H, Qiao J, Pu F, Jiang J, Hubbard K . Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc Natl Acad Sci U S A. 2015; 112(21):6607-12. PMC: 4450423. DOI: 10.1073/pnas.1423021112. View

17.

Clough T, Jiang L, Wong K, Long N . Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. Nat Commun. 2019; 10(1):1420. PMC: 6441101. DOI: 10.1038/s41467-019-09342-3. View

18.

Longo D, Arena F, Consolino L, Minazzi P, Geninatti-Crich S, Giovenzana G . Gd-AAZTA-MADEC, an improved blood pool agent for DCE-MRI studies on mice on 1 T scanners. Biomaterials. 2015; 75:47-57. DOI: 10.1016/j.biomaterials.2015.10.012. View

19.

Rolla G, Platas-Iglesias C, Botta M, Tei L, Helm L . 1H and 17O NMR relaxometric and computational study on macrocyclic Mn(II) complexes. Inorg Chem. 2013; 52(6):3268-79. DOI: 10.1021/ic302785m. View

20.

Grobner T . Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006; 21(4):1104-8. DOI: 10.1093/ndt/gfk062. View